Prostatype Genomics AB (publ) (STO:PROGEN)
0.5400
+0.0950 (21.35%)
Jun 5, 2026, 5:29 PM CET
Prostatype Genomics AB Market Cap
Prostatype Genomics AB has a market cap or net worth of 31.96 million as of June 5, 2026. Its market cap has increased by 216.75% in one year.
Market Cap
31.96M
Enterprise Value
22.89M
Revenue
594.00K
Ranking
n/a
PE Ratio
n/a
Stock Price
0.54
Market Cap Chart
Since November 3, 2020, Prostatype Genomics AB's market cap has decreased from 92.30M to 31.96M, a decrease of -65.37%. That is a compound annual growth rate of -17.28%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 5, 2026 | 31.96M | 80.00% |
| Dec 30, 2025 | 17.76M | -76.14% |
| Dec 30, 2024 | 74.42M | 555.78% |
| Dec 29, 2023 | 11.35M | -76.58% |
| Dec 30, 2022 | 48.46M | -64.07% |
| Dec 30, 2021 | 134.89M | -28.46% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Nov 3, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Swedish Orphan Biovitrum AB | 154.04B |
| Sectra AB | 57.15B |
| Getinge AB | 52.94B |
| Camurus AB | 32.09B |
| Perpetua Medical AB | 31.67M |
| Gabather AB | 30.04M |
| Guard Therapeutics International AB | 29.04M |
| Aino Health AB | 25.37M |